Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Umbilical cord mesenchymal stem cell therapy - Sclnow Biotechnology

Drug Profile

Umbilical cord mesenchymal stem cell therapy - Sclnow Biotechnology

Alternative Names: 19#iSCLife®-CSD; Cord blood stem cell therapy - Sclnow Biotechnology; hUC Mesenchymal Stem Cells - Sclnow Biotechnology; hUC-MSC; hUC-MSC - Sclnow Biotechnology; Human umbilical cord mesenchymal stem cells - Sclnow Biotechnology; SCLnow 19; Umbilical cord derived allogeneic mesenchymal stem cells therapy - Sclnow Biotechnology

Latest Information Update: 28 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sclnow Biotechnology
  • Class Antineoplastics; Heart failure therapies; Hepatoprotectants; Mesenchymal stem cell therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Wounds
  • Phase II Osteoarthritis; Primary ovarian insufficiency
  • No development reported Cerebral infarction; Femur head necrosis; Heart failure; Liver cirrhosis; Myelodysplastic syndromes

Most Recent Events

  • 28 Nov 2023 No recent reports of development identified for phase-I development in Cerebral-infarction in China (IV, Injection)
  • 28 Nov 2021 No recent reports of development identified for phase-I development in Liver-Cirrhosis in China (IV, Injection)
  • 21 Sep 2021 Sclnow Biotechnology completes a phase III trial in Wounds in China (Intrauterine) (NCT03386708)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top